The Quantellect read.As of Nov 19, 2026, 5 active firms cover Avita Medical Ltd: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $10.00 to $15.00, a moderate spread. The average target of $12.75 sits 24% below the current $16.78. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.26 next quarter toward $-0.32 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$12.75
-24.0% downside
Average target across 4 active firms as of Nov 19, 2026 vs $16.78 current
Highest Target$15.00
Average Target$12.75
Lowest Target$10.00
Detailed analyst forecasts for RCEL
Showing 1–4 of 4 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate RCEL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RCEL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.26
Range $-0.31 – $-0.22 · 2 analysts · -46% YoY
Next period, 2 analysts expect Avita Medical Ltd to earn $-0.26 a share (range $-0.31 – $-0.22), versus $-0.48 a year earlier. Full-year consensus is $0.42, growing to $-0.32 the year after.
REVENUE · NEXT QUARTER
$36.2M
Range $35.2M – $38.5M · 2 analysts · +36% YoY
Revenue is expected to reach $36.2M (range $35.2M – $38.5M), +35.8% year-over-year. Full-year consensus is $135.0M, rising to $166.7M next year.
Top analysts covering Avita Medical Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RCEL.
#1
Ryan Zimmerman
BTIG · Rank #212
Buy
$15.00-10.6% to target
Overall win rate
37%
+ Follow
#2
Ross Osborn
Cantor Fitzgerald · Rank #238
Buy
$11.00-34.4% to target
Overall win rate
34%
+ Follow
#3
Frank Takkinen
Lake Street · Rank #514
Buy
$12.00-28.5% to target
Overall win rate
27%
+ Follow
#4
Jason Kolbert
D. Boral Capital · Rank #562
Buy
$10.00-40.4% to target
Overall win rate
22%
+ Follow
#5
JJ
Joshua Jennings
TD Cowen
Buy
$14.00-16.6% to target
Coverage
—
+ Follow
RCEL stock forecast FAQ
What is RCEL's average 12-month price target?+
The 4 active firms with a live target average $12.75 for Avita Medical Ltd over the next 12 months, ranging from a $15.00 high to a $10.00 low, as of Nov 19, 2026.
Is RCEL stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RCEL?+
The Street-high target is $15.00 (BTIG), and the Street-low is $10.00 (D. Boral Capital). The average of all 4 active-firm targets is $12.75.
How many active Wall Street firms cover RCEL?+
5 active firms have a recognized rating on Avita Medical Ltd as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RCEL?+
Among analysts who currently cover RCEL, Ryan Zimmerman of BTIG has the strongest overall Quantellect track record (Rank #212). Their current call is Buy with a $15.00 target.
What is Avita Medical Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.26 per share (range $-0.31 – $-0.22) across 2 analysts. Full-year EPS is projected at $0.42, rising to $-0.32 the following year.
How much revenue is Avita Medical Ltd expected to report next quarter?+
Consensus revenue is $36.2M (range $35.2M – $38.5M). Full-year revenue is projected at $135.0M, growing to $166.7M next year.
Have analysts been upgrading or downgrading RCEL lately?+
As of Nov 19, 2026, 5 of 5 active firms rate RCEL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RCEL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.